XML 360 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Share-based Payments (Tables)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payments [Abstract]    
Disclosure of Share-based Payment Expense Table
The following table provides the classification of the Group’s consolidated share-based payment expense as reflected in the Consolidated Statement of Income/(Loss):
Year ended December 31,
2021
$000s
2020
$000s
2019
$000s
General and administrative9,310 7,650 10,677 
Research and development4,640 3,068 3,791 
Total13,950 10,718 14,468 
  
Disclosure of RSU activity
RSU activity for the years ended December 31, 2021, 2020 and 2019 is detailed as follows:
Number of Shares/UnitsWtd Avg Grant Date Fair Value (GBP) (*)
Outstanding (Non-vested) at January 1, 20196,598,783 1.29 
RSUs Granted in Period1,775,569 2.95 
Vested(3,738,005)1.10 
Forfeited— — 
Outstanding (Non-vested) at December 31, 2019 and January 1, 20204,636,347 2.08 
RSUs Granted in Period1,759,011 1.80 
Vested(2,781,687)1.54 
Forfeited(191,089)2.37 
Outstanding (Non-vested) at December 31, 2020 and January 1, 20213,422,582 2.46 
RSUs Granted in Period2,195,133 2.15 
Vested(1,176,695)2.93 
Forfeited(808,305)2.25 
Outstanding (Non-vested) at December 31, 20213,632,715 1.91 
  
Disclosure of stock option activity Stock option activity for the years ended December 31, 2021, 2020 and 2019, is detailed as follows:
Number of OptionsWtd Average Exercise Price (GBP)Wtd Average of
remaining contractual
term (in years)		Wtd Average Stock Price at Exercise (GBP)
Outstanding at January 1, 20195,075,734 1.40 8.78
Granted3,634,183 0.84 
Exercised(237,090)1.98 2.81
Forfeited— — 
Options Exercisable at December 31, 2019 and January 1, 20204,349,921 0.93 8.34
Outstanding at December 31, 2019 and January 1, 20208,472,827 1.16 8.55
Granted4,076,982 3.14 
Exercised(514,410)1.52 2.88
Forfeited(1,119,313)1.88 
Options Exercisable at December 31, 2020 and January 1, 20215,447,405 0.98 7.46
Outstanding at December 31, 2020 and January 1, 202110,916,086 1.81 8.38
Granted5,424,000 3.34 
Exercised(2,238,187)0.70 3.63
Forfeited(687,781)2.53 
Options Exercisable at December 31, 20214,773,873 1.42 6.50
Outstanding at December 31, 202113,414,118 2.58 8.29
  
Disclosure of terms and conditions of share-based payment arrangement
The fair value of the stock options awarded by the Company was estimated at the grant date using the Black-Scholes option valuation model, considering the terms and conditions upon which options were granted, with the following weighted-average assumptions:
At December 31,
2021
2020
2019
Expected volatility41.05 %41.25 %35.68 %
Expected terms (in years)6.166.115.81
Risk-free interest rate1.06 %0.53 %1.85 %
Expected dividend yield— — — 
Grant date fair value$1.87 $1.72 $2.23 
  
Disclosure of range of exercise prices of outstanding share options
For shares outstanding as of December 31, 2021, the range of exercise prices is detailed as follow:
Range of Exercise Prices (GBP)Options
Outstanding		Wtd
Average
Exercise
Price (GBP)		Wtd Average of
remaining contractual
term (in years)
0.01
842,762 — 7.76
1.00 to 2.00
3,521,839 1.42 5.81
2.00 to 3.00
1,251,017 2.47 8.35
3.00 to 4.00
7,798,500 3.39 9.46
Total13,414,118 2.58 8.29
  
Disclosure of Subsidiary Share-based Payments
Subsidiary Plans
Certain subsidiaries of the Group have adopted stock option plans. A summary of stock option activity by number of shares in these subsidiaries is presented in the following table:
Outstanding as of January 1, 2021
Granted During the YearExercised During the YearExpired During the YearForfeited During the Year
Outstanding as of December 31, 2021
Alivio3,888,168 197,398 (2,373,750)(506,260)(1,205,556)— 
Entrega962,000 — (525,000)(87,500)— 349,500 
Follica1,309,040 1,383,080 — (6,000)— 2,686,120 
Sonde2,192,834 — — (51,507)(92,323)2,049,004 
Vedanta1,741,888 451,532 (52,938)(76,491)(72,354)1,991,637 
Outstanding as of January 1, 2020
Granted During the YearExercised During the YearExpired During the YearForfeited During the Year
Outstanding as of December 31, 2020
Alivio3,698,244 189,924 — — — 3,888,168 
Entrega972,000 — — — (10,000)962,000 
Follica1,309,040 — — — — 1,309,040 
Sonde1,829,004 363,830 — — — 2,192,834 
Vedanta1,450,100 493,951 (813)— (201,350)1,741,888 
Outstanding as of January 1, 2019
Granted During the YearExercised During the YearExpired During the YearForfeited During the Year
Outstanding as of December 31, 2019
Gelesis3,681,732 — — (110,386)(3,571,346)¹— 
Alivio2,393,750 1,329,494 (3,125)— (21,875)3,698,244 
PureTech LYT2,180,000 — — — (2,180,000)²— 
Commense540,416 — — — (540,416)— 
Entrega914,000 58,000 — — — 972,000 
Follica1,229,452 79,588 — — — 1,309,040 
Karuna1,949,927 — — — (1,949,927)¹— 
Sonde22,500 1,806,504 — — — 1,829,004 
Vedanta1,373,750 154,193 — — (77,843)1,450,100 
1    These shares represent the options outstanding on the date of deconsolidation of Karuna and Gelesis.
2    These shares represent the options outstanding on the date of exchange to PureTech stock options.
  
Disclosure of Weighted Average Exercise Prices for Options Outstanding
The weighted-average exercise prices and remaining contractual life for the options outstanding as of December 31, 2021, were as follows:
Outstanding at December 31, 2021
Number of options
Weighted-average exercise price
$
Weighted-average contractual life outstanding
Alivio— — 0
Entrega349,500 1.88 4.62
Follica2,686,120 1.39 7.28
Sonde2,049,004 0.20 7.71
Vedanta1,991,637 13.42 5.92
  
Disclosure of Weighted Average Exercise Prices for Options Granted
The weighted average exercise prices for the options granted for the years ended December 31, 2021, 2020 and 2019, were as follows:
For the years ended December 31,
2021
$
2020
$
2019
$
Alivio— 0.47 0.49 
Follica1.86 — 0.03 
Sonde— 0.18 0.20 
Vedanta19.69 19.59 19.13 
  
Disclosure of Weighted Average Exercise Prices for Options Forfeited
The weighted average exercise prices for options forfeited during the year ended December 31, 2021, were as follows:
Forfeited during the year ended December 31, 2021Number of options
Weighted-average exercise price
$
Alivio1,205,556 0.48 
Sonde92,323 0.18 
Vedanta72,354 19.36 
  
Disclosure of Weighted Average Exercise Prices for Options Exercised
The weighted average exercise prices for options exercised during the year ended December 31, 2021, were as follows:
Exercised during the year ended December 31, 2021Number of optionsWeighted-average exercise price
$
Alivio2,373,750 0.03 
Entrega525,000 0.03 
Vedanta52,938 0.96 
  
Disclosure of Weighted Average Exercise Prices for Options Exercisable
The weighted average exercise prices for options exercisable as of December 31, 2021, were as follows:
Exercisable at December 31, 2021Number of Options
Weighted-average exercise price
$
Exercise Price Range
$
Alivio— — 
—
Entrega349,500 1.88
0.03-2.36
Follica2,686,120 1.01
0.03-1.86
Sonde2,049,0040.20
0.13-0.20
Vedanta1,991,6379.64
0.02-19.94
  
Significant Subsidiary Plan -Vedanta 2010 Plan - Range of assumptions of Fair Value of stock option grants  
The fair value of the stock option grants has been estimated at the date of grant using the Black-Scholes option pricing model with the following range of assumptions:
Assumption/Input
2021
2020
2019
Expected award life (in years)
6.00-7.11
6.00-10.00
5.86-6.07
Expected award price volatility
88.05%-88.59%
89.24%-95.46%
89.24%-95.46%
Risk free interest rate
0.96%-1.32%
0.32%-0.87%
1.73%-1.88%
Expected dividend yield———
Grant date fair value
$13.84-$16.23
$13.09-$16.54
$14.12-$15.61
Share price at grant date
$19.00-$21.35
$19.59
$18.71-$19.94